Dimensional Fund Advisors
TRVI icon

Dimensional Fund Advisors’s Trevi Therapeutics TRVI Stock Holding History

Dimensional Fund Advisors’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-16,101
Closed -$192K – 3304
2026
Q1 		$192K Sell
16,101
-20,409
-56% -$228K ﹤0.01% 3071
2025
Q4 		$457K Sell
36,510
-4,933
-12% -$57K ﹤0.01% 2981
2025
Q3 		$379K Sell
41,443
-85,481
-67% -$641K ﹤0.01% 3036
2025
Q2 		$695K Hold
126,924
– – ﹤0.01% 2938
2025
Q1 		$799K Sell
126,924
-7,429
-6% -$35.4K ﹤0.01% 2921
2024
Q4 		$553K Buy
134,353
+62,143
+86% +$199K ﹤0.01% 3016
2024
Q3 		$241K Hold
72,210
– – ﹤0.01% 3140
2024
Q2 		$215K Buy
72,210
+49,475
+218% +$137K ﹤0.01% 3153
2024
Q1 		$78.4K Buy
+22,735
New +$50.7K ﹤0.01% 3290
2023
Q4 		– Sell
-18,382
Closed -$40.1K – 3456
2023
Q3 		$40.1K Buy
+18,382
New +$41.5K ﹤0.01% 3396

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

Dimensional Fund Advisors's TRVI Position: Q2 2026 in Review

Dimensional Fund Advisors sold out of Trevi Therapeutics (TRVI) in Q2 2026, closing a stake of 16,101 shares — an estimated $192K sold.

Dimensional Fund Advisors first reported a position in TRVI in Q3 2023 and held it in 10 quarters. The position peaked at $799K in Q1 2025. 218 funds tracked by Wall St. Rank hold TRVI as of Q2 2026.

  • Dimensional Fund Advisors reported no remaining Trevi Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Dimensional Fund Advisors sold 16,101 Trevi Therapeutics shares in Q2 2026, an estimated $192K.
  • Dimensional Fund Advisors first reported a position in Trevi Therapeutics in Q3 2023 and held it in 10 quarters.
  • Dimensional Fund Advisors's Trevi Therapeutics position peaked at $799K in Q1 2025.
  • 218 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q2 2026.

Based on Dimensional Fund Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.